三阴乳腺癌的最新治疗进展.pdfVIP

1234 中国肿瘤临床 2011 年第38 卷第19期 三阴乳腺癌的最新治疗进展 马 静 综述 魏素菊 审校 摘要 近年在发达国家，乳腺癌的死亡率显著降低，但几乎所有的生存受益均来自于激素受体或HER-2 受体阳性的乳腺癌 患者。三阴乳腺癌是指雌激素受体（ER ）、孕激素受体（PR ）、表皮生长因子受体2 （HER 2 ）均为阴性的乳腺癌，约占所有乳腺癌的 15% ，虽对化疗敏感但较激素受体阳性及HER-2 受体阴性的乳腺癌预后差。它是一种高度异质性的肿瘤且不能从内分泌或曲妥 珠单抗治疗中获益，故化疗为其唯一的全身治疗手段。最新的临床研究结果显示，在紫杉类/ 蒽环类为基础的传统化疗方案的基 础上加用希罗达能显著改善三阴乳腺癌患者的无复发生存期（RFS）和总生存期（OS）。三阴乳腺癌与BRCA1 突变之间有着一定 的联系，尽管其机制未明但可以此为突破点作为治疗选择。多聚ADP 核糖聚合酶抑制剂BSI-201 和olaparib、抗血管生成因子及 表皮生长因子抑制剂在三阴乳腺癌的治疗中均显示了较高的有效率。关注这些最新的治疗进展将有助于发现新的治疗途径及 寻找出标准的治疗三阴乳腺癌的化疗方案。 关键词 三阴乳腺癌 希罗达 PARP- 1抑制剂 抗血管生成因子 EGFR 抑制剂 doi:10.3969/j.issn. 1000-8179.2011.19.015 Latest Development in Treatment of Triple-Negative Breast Cancer Jing MA, Suju WEI Correspondence to: Suju WEI, E-mail: weisuju@126.com Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China Abstract There has been a remarkable decrease in mortality caused by breast cancer in developed countries over the past few years. Nearly all benefits are found in patients with hormone receptor and/or human epidermal growth factor receptor (HER)-2-positive breast cancer. Triple-negative breast cancer denotes tumors that do not express the estrogen receptor, progesterone receptor, and HER-2 genes that accounts for approximately 15% of breast cancer. This cancer is more chemosensitive but has a worse prognosis compared with the HR-positive/HER-2-negative phenotype. Triple-negative breast cancer is a highly heterogeneous disease but is not treatable by endocrine or trastuzumab therapy. Therefore, the standard chemotherapy, such as the combination of anthracycline and taxane, is the on- ly feasible method of systemic therapy. Latest results of clinical research have demonstrated that taxane/anthracycline-based convention- al chemotherapeutic regimens